• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Altria Group Inc.

    8/6/25 4:57:40 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    8-K
    false 0000764180 0000764180 2025-08-06 2025-08-06 0000764180 mo:CommonStock0.3313ParValueMember 2025-08-06 2025-08-06 0000764180 mo:CommonStock2.200NotesDue2027Member 2025-08-06 2025-08-06 0000764180 mo:CommonStock3.125NotesDue2031Member 2025-08-06 2025-08-06
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 6, 2025

     

     

    ALTRIA GROUP, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Virginia   1-08940   13-3260245
    (State or other jurisdiction
    of incorporation)
      (Commission File
    Number)
      (I.R.S. Employer
    Identification No.)

     

    6601 West Broad Street, Richmond, Virginia   23230
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (804) 274-2200

     

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbols

     

    Name of each exchange
    on which registered

    Common Stock, $0.33 1/3 par value   MO   New York Stock Exchange
    2.200% Notes due 2027   MO27   New York Stock Exchange
    3.125% Notes due 2031   MO31   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 8.01.

    Other Events.

    On August 6, 2025, Altria Group, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 4.500% Notes due 2030 (the “2030 Notes”) and $500,000,000 aggregate principal amount of its 5.250% Notes due 2035 (the “2035 Notes” and, together with the 2030 Notes, the “Notes”). The Notes were issued pursuant to an Indenture (the “Indenture”), dated as of November 4, 2008, among the Company, Philip Morris USA Inc., a wholly owned subsidiary of the Company (“PM USA”), and Deutsche Bank Trust Company Americas, as trustee (the “Trustee”). Each series of Notes is guaranteed by PM USA. PM USA’s guarantees were issued pursuant to the Indenture and are evidenced by guarantee agreements made by PM USA in favor of the Trustee for the Notes (the “Guarantee Agreements”).

    The Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of the Company’s existing and future senior unsecured indebtedness. The Guarantee Agreements are PM USA’s senior unsecured obligations and rank equally in right of payment with all of PM USA’s existing and future senior unsecured indebtedness.

    On August 4, 2025, the Company and PM USA entered into a Terms Agreement (the “Terms Agreement”) with Barclays Capital Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell the Notes to the Underwriters. The provisions of an Underwriting Agreement, dated as of November 4, 2008 (the “Underwriting Agreement”), are incorporated by reference in the Terms Agreement.

    Interest on the 2030 Notes is payable semiannually on February 6 and August 6 of each year, commencing February 6, 2026, to holders of record on the preceding January 22 or July 22, as the case may be. Interest on the 2035 Notes is payable semiannually on February 6 and August 6 of each year, commencing February 6, 2026, to holders of record on the preceding January 22 or July 22, as the case may be.

    The 2030 Notes will mature on August 6, 2030 and the 2035 Notes will mature on August 6, 2035.

    The Company has filed a Prospectus, dated October 26, 2023 (Registration No. 333-275173), and a Prospectus Supplement, dated August 4, 2025, with the Securities and Exchange Commission in connection with the public offering of the Notes.

    The descriptions of the Underwriting Agreement, the Terms Agreement and the Guarantee Agreements are qualified in their entirety by the terms of such agreements themselves. Please refer to such agreements, the Indenture and the form of Notes, each of which is incorporated herein by reference and is an exhibit to this report as Exhibits 1.1, 1.2, 4.1, 4.2, 4.3, 4.4 and 4.5.

     

    Item 9.01.

    Financial Statements and Exhibits.

     

    (d)

    Exhibits

     

    1.1    Underwriting Agreement, dated November 4, 2008 (incorporated by reference to Exhibit 1.1 of the Company’s Registration Statement on Form S-3 filed on November 4, 2008 (No. 333-155009))
    1.2    Terms Agreement, dated August 4, 2025, among the Company, Barclays Capital Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein
    4.1    Indenture among Altria Group, Inc., as Issuer, Philip Morris USA Inc., as Guarantor, and Deutsche Bank Trust Company Americas, as Trustee, dated as of November 4, 2008 (incorporated by reference to Altria Group, Inc.’s Registration Statement on Form S-3 filed on November 4, 2008 (No. 333-155009))
    4.2    Guarantee Agreement 4.500% Notes due 2030
    4.3    Guarantee Agreement 5.250% Notes due 2035
    4.4    Form of 4.500% Notes due 2030
    4.5    Form of 5.250% Notes due 2035
    5.1    Opinion of McGuireWoods LLP
    104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101)

     

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    ALTRIA GROUP, INC.
    By:  

    /s/ W. Hildebrandt Surgner, Jr.

    Name:   W. Hildebrandt Surgner, Jr.
    Title:   Vice President, Corporate Secretary and
    Associate General Counsel

    DATE:  August 6, 2025

     

    3

    Get the next $MO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    7/9/2025$50.00Underperform
    Jefferies
    7/2/2025$59.00Sell → Neutral
    UBS
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    More analyst ratings

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altria Reports 2025 Second-Quarter and First-Half Results; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 second-quarter and first-half business results and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses," said Billy Gifford, Altria's Chief Executive Officer. "In oral tobacco, on! delivered strong performance and was the substantial driver of the segment's growth in the quarter. And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases." "We are raising the lower-end of ou

    7/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast of 2025 Second-Quarter and First-Half Results

    Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 second-quarter and first-half business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com. During the webcast, Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Chief Financial Officer, will discuss the Company's 2025 second-quarter and first-half business results and answer questions from the investment community and news media. The webcast will be in a listen-only mode. Pre-event registration is neces

    7/16/25 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

    5/15/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Patterson Katie F claimed ownership of 17,191 shares (SEC Form 3)

    3 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    8/1/25 2:37:57 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Yzaguirre Mario Max was granted 3,219 shares, increasing direct ownership by 25% to 16,252 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:06:43 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Strahlman Ellen R was granted 3,219 shares, increasing direct ownership by 16% to 23,087 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/19/25 3:05:17 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:08:44 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:03:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Altria with a new price target

    Jefferies resumed coverage of Altria with a rating of Underperform and set a new price target of $50.00

    7/9/25 8:26:04 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

    7/2/25 7:43:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria downgraded by Deutsche Bank

    Deutsche Bank downgraded Altria from Buy to Hold

    4/1/25 3:04:54 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    SEC Filings

    View All

    SEC Form 8-K filed by Altria Group Inc.

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    8/6/25 4:57:40 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form FWP filed by Altria Group Inc.

    FWP - ALTRIA GROUP, INC. (0000764180) (Subject)

    8/4/25 4:58:18 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Altria Group Inc.

    10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

    7/30/25 7:22:57 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    View All

    Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

    Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

    2/26/24 4:30:00 PM ET
    $ARIS
    $MO
    $PXD
    Oilfield Services/Equipment
    Energy
    Medicinal Chemicals and Botanical Products
    Health Care

    Seasoned Financial Expert Max Yzaguirre Named Strategic Advisor of FireFly Automatix, Leader in AV and EV-Driven Professional Turfgrass Mowing Technology

    -Yzaguirre joins a list of seasoned professionals on FireFly's team with specific expertise in initiating and growing businesses in evolving market conditions- FireFly Automatix, Inc., the de facto industry leader in AV and EV professional turfgrass mowing technology, today announced the appointment of financial and leadership expert M. Max Yzaguirre as a strategic advisor to CEO Andrew Limpert and the board of directors. Yzaguirre's appointment follows the recent additions of former WPP Group CFO Paul Richardson and capital markets professional Liz Hocker to FireFly's board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202401

    1/23/24 9:00:00 AM ET
    $ARIS
    $LBC
    $MO
    Oilfield Services/Equipment
    Energy
    Major Banks
    Finance

    Altria Group, Inc. Announces Retirement of Director Nabil Y. Sakkab From Board of Directors

    Nabil Y. Sakkab, a director of Altria Group, Inc. ("Altria") since 2008, will retire from service on our Board of Directors following the completion of his current term. Consequently, Mr. Sakkab will not stand for re-election to the Board of Directors at Altria's 2024 Annual Meeting of Shareholders, which Altria anticipates holding on May 16, 2024. "Nabil's contributions have significantly benefited Altria over the past 15 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank him for his long and distinguished service and wish him the very best upon his retirement." Dr. Sakkab is Chair of the Innovation Committee and is a member of the Executive, Finance, and

    10/25/23 4:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Financials

    Live finance-specific insights

    View All

    Altria Reports 2025 Second-Quarter and First-Half Results; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 second-quarter and first-half business results and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "In the second quarter, we continued the pursuit of our Vision while maintaining our strong and profitable core businesses," said Billy Gifford, Altria's Chief Executive Officer. "In oral tobacco, on! delivered strong performance and was the substantial driver of the segment's growth in the quarter. And we returned significant value to our loyal shareholders during the first-half of the year, with more than $4 billion delivered through dividends and share repurchases." "We are raising the lower-end of ou

    7/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

    5/15/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

    4/29/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/24 4:58:48 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/23 2:49:28 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/9/23 10:54:46 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care